Nov.22 -- Rajeev Venkayya, president of the global vaccine business unit of Japan's Takeda Pharmaceutical Co., discusses the latest developments in the global race for Covid-19 vaccines. The company said last month it will import and distribute Moderna Inc.’s Covid-19 vaccine candidate starting in the first half of 2021. The move follows Takeda’s announcement that it is establishing the capability to manufacture Novavax Inc.’s vaccine candidate at its facilities. Venkayya, who previously worked at the White House as a special assistant to the president for biodefense, speaks on "Bloomberg Markets: Asia."